Drug Profile
Research programme: ophthalmic sirolimus - Advanced Ocular Systems/Novelion Therapeutics
Latest Information Update: 30 Nov 2016
Price :
$50
*
At a glance
- Originator Advanced Ocular Systems
- Class
- Mechanism of Action B cell inhibitors; T lymphocyte inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Eye disorders
Most Recent Events
- 29 Nov 2016 QLT acquired Aegerion Pharmaceuticals and later QLT changed its name to Novelion Therapeutics
- 29 May 2006 Preclinical trials in Eye disorders in Australia (unspecified route)